Avanza Fonder AB Buys Shares of 2,605 Janux Therapeutics, Inc. (NASDAQ:JANX)

Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,605 shares of the company’s stock, valued at approximately $139,000.

A number of other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC lifted its position in Janux Therapeutics by 40.0% during the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after acquiring an additional 721,563 shares during the last quarter. Logos Global Management LP increased its position in shares of Janux Therapeutics by 400.0% during the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after purchasing an additional 600,000 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Janux Therapeutics by 190.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after purchasing an additional 259,445 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after buying an additional 156,675 shares during the last quarter. Finally, Barclays PLC increased its position in Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after buying an additional 144,883 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Price Performance

NASDAQ:JANX opened at $40.72 on Monday. The company has a 50 day moving average price of $53.09 and a 200-day moving average price of $48.41. Janux Therapeutics, Inc. has a 1-year low of $7.79 and a 1-year high of $71.71. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of -34.80 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. The company’s quarterly revenue was down 82.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

JANX has been the subject of several recent analyst reports. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Scotiabank raised their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 4th. Stifel Nicolaus upped their target price on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Finally, UBS Group began coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $89.90.

Insider Buying and Selling

In related news, CEO David Alan Campbell sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now directly owns 293,054 shares in the company, valued at approximately $17,583,240. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew Hollman Meyer sold 13,334 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the transaction, the insider now owns 82,139 shares in the company, valued at $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 108,334 shares of company stock valued at $6,070,020. 29.40% of the stock is owned by company insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.